[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polypharmacy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polypharmacy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,51,79,111,142,165,196,220,263,290,314,377,406],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100638389","effectiveness-of-health-literacy-program-for-polypharmacy-patients-hlp-ckd-100638389",false,"NCT07622134","Effectiveness of Health Literacy Program for Polypharmacy Patients (HLP-CKD)","Effectiveness of the Health Literacy Promotion Program to Prevent Chronic Kidney Disease of Patients Who Use Polypharmacy","HLP-CKD","Inclusion Criteria:\n\n* Patients aged 55-74 years diagnosed with non-communicable diseases.\n* Currently taking 5 or more medications daily (Polypharmacy) for at least 6 months.\n* Have at least one risk factor for chronic kidney disease (e.g., Hypertension or Diabetes).\n* Able to communicate, read, and write in Thai.\n* Willing to participate in the 8-week program and follow-up assessments.\n\nExclusion Criteria:\n\n* Patients already diagnosed with Chronic Kidney Disease (CKD) stage 3 - 5.\n* Having severe cognitive impairment or psychiatric disorders that prevent participation.\n* Having severe complications or being in an unstable clinical condition.\n* Planning to move out of the study area during the 12-week study period.","ALL","55 Years","74 Years",{"count":21,"type":22},104,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to evaluate the effectiveness of a health literacy promotion program in preventing chronic kidney disease (CKD) among patients who use multiple medications (polypharmacy). Participants will be divided into two groups: an experimental group receiving the health literacy program and a control group receiving standard care. The study will measure improvements in health literacy levels and CKD prevention behaviors over a specific period. It is expected that the program will help patients better manage their medications and reduce the risk of developing kidney complications.",[28,29,30],"Chronic Kidney Diseases","Polypharmacy","Health Literacy",[32,33,34,35,36,37],"Health Literacy Program","CKD Prevention","Medication Management","Nursing Intervention","Randomized Controlled Trial","Thailand","NOT_YET_RECRUITING","2026-06-03",{"date":41,"type":42},"2026-06-04","ACTUAL",{"date":44,"type":22},"2026-06-15",{"date":46,"type":22},"2026-11-15",{"name":48,"class":49},"Nakhon Pathom Rajabhat University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":50},"100585470","evaluation-of-the-impact-of-a-collaboration-between-hospital-and-community-pharmacists-at-hospital-discharge-100585470","NCT06902779","Evaluation of the Impact of a Collaboration Between Hospital and Community Pharmacists at Hospital Discharge","Enhanced Collaboration Between Hospital and Community Pharmacists to Improve the Hospital Discharge Process","Inclusion Criteria:\n\n* Patients admitted to the internal medicine ward for more than 48 hours\n* Patients prescribed seven or more drugs at the time of screening\n* Patients discharged to home\n* Patients able to give informed consent as documented by signature\n\nExclusion Criteria:\n\n* Patient discharged to another hospital, nursing home or rehabilitation clinic\n* Refusal of the community pharmacy to participate\n* Inability to sign consent and follow the procedures of the study, due to language problems, psychological disorders, dementia, alterations of consciousness and lack of judgement","18 Years",{"count":60,"type":22},150,[25],"The aim of this study is to evaluate the impact of an enhanced collaboration between a hospital pharmacist and a community pharmacist during hospital discharge. For patients taking multiple medications, hospitalization often involves numerous changes to their treatment regimen. For community pharmacies, discharge prescriptions are often complex, and they sometimes lack the information that pharmacists need to deliver the treatment as safely as possible. As a result, there is a risk of medication errors, and a risk for patients. We aim to evaluate the benefits of this collaboration for adult patients admitted to the internal medicine ward of a regional hospital who are taking seven or more drugs and are being discharged to home.\n\nThe main question it aims to answer is : Does the enhanced collaboration reduce the number of drug-related problems encountered by community pharmacists with discharge prescriptions ? Researchers will compare patients when a hospital pharmacist is involved during the discharge process and when he or she is not involved, which corresponds to normal care.\n\nThe hospital pharmacist will not perform the intervention directly on the patient, but only with the community pharmacy. Once they agree to participate in the study, patients will only have to go to their usual community pharmacy after discharge and accept that the hospital transmits medical information to their usual pharmacy.",[29],[65,66,67,68],"transition of care","pharmacists","hospital discharge","collaboration","RECRUITING","2026-04-13",{"date":72,"type":42},"2026-04-16",{"date":74,"type":42},"2025-09-01",{"date":76,"type":22},"2026-10",{"name":78,"class":49},"Pharmacie des Hopitaux de l'Est Lemanique",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":50},"100550793","prioritising-patient-medication-review-hospitals-reaching-out-100550793","NCT06451692","Prioritising Patient Medication Review: Hospitals Reaching Out","Prioritising Patient Medication Review: Hospitals Reaching Out (PriPMed)","PriPMed","Inclusion Criteria:\n\n* all hospitalized patients who are prescribed at least seven medications specified in the Electronic Patient Journal (EPJ) at admission\n\nExclusion Criteria:\n\n* terminal patients or patients with a short life expectancy, patients residing in another region, patients who are discharged on the day of inclusion, and finally patients who do not speak Danish.","65 Years",{"count":89,"type":22},800,[25],"To examine the effect of a cross-sectoral medication review intervention to admitted multi-morbid, polypharmacy patients aged 65+ at SHS in two settings; an acute admission unit (typical admission time \\\u003C 48 hours) and a medical outpatient setting (patients routinely visits for follow-up, diagnosis or treatment, but do require a bed or overnight care).",[93,29,94,95,96],"Medication Review","General Practitioners","Interdisciplinary Communication","Clinical Pharmacy",[98,99,100,101,102,29],"Multi-morbidity","Medication review","Dementia","Clinical Fragility scale","Hospital to home transition","2026-04-08",{"date":70,"type":42},{"date":106,"type":42},"2024-06-17",{"date":108,"type":22},"2027-06-01",{"name":110,"class":49},"University of Southern Denmark",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":128,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":50},"100528356","telecommunication-technology-based-online-survey-100528356","NCT06159699","Telecommunication Technology-based Online Survey","New Challenges for the Population on the Path to Achieving Active Longevity: an Online Survey of Respondents Using Telecommunication Technologies","Inclusion Criteria:\n\n* age of 18 years and older\n* signing the informed concent form online\n* completion of the entire questionnaire\n\nExclusion Criteria:\n\n* age under 18 years\n* refuse to sign the informed concent form",true,{"count":120,"type":22},2000,"OBSERVATIONAL","The aim of this study is to identify and assess new health-associated risk factors, including clinical-pharmacological risk factors. The cohort is built using telecommunication approaches. The associations between clinical-pharmacological, social, demographic, behavioral, and environmental characteristics will be assessed. The continuous depersonalized online survey is performed using the original informational resources in the form of specially designed web-site aimed at identification and assessment of population-based pharmacotherapy patterns including characteristics of self-medication, biologically active food supplement intake, polypharmacy, and adverse drug-drug interactions in the people residing in the ecological conditions of various regions of the country. The invitations to participate in the online survey are sent via the SMS messages using the SMS-Target tool provided by OOO T2 Mobile Company. The survey is performed online at www.zdorov.tpu.ru and www.zdorov.expert both specifically designed for questionnaire publication and data accumulation.",[124,29,125,126,127],"Risk Factors","Drug Interactions","Self Medication","COVID-19",[29,129,126,127,130,131,132],"Potential Drug-Drug Interactions","Medical Imaging","Environmental Risk Factors","Protracted Low-Dose-Rate Radiation Exposure","2026-01-23",{"date":135,"type":42},"2026-01-27",{"date":137,"type":42},"2022-12-02",{"date":139,"type":22},"2028-12-31",{"name":141,"class":49},"Tomsk National Research Medical Center of the Russian Academy of Sciences",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100589623","empowering-patients-to-improve-safety-in-polymedication-100589623","NCT06956820","Empowering Patients to Improve Safety in Polymedication","Empowering Patients to Improve Safety in Polymedication (EmPaSafe)","EmpaSafe","In order to be eligible to participate in this study, a subject must meet all of the following crite-ria:\n\n* Polypharmacy defined as the use of 5 or more drugs\n* Start usage of at least one index drug according to the list in table 3.\n* Subject must be ≥ 18 years old\n* Subject is able and willing to take part and be followed-up for at least 12 weeks\n* Subject is able to donate blood or saliva\n* Subject has signed informed consent\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Pregnancy or lactating\n* Life expectancy estimated to be less than three months by treating clinical team\n* Unable to consent to the study\n* Unwilling to take part\n* Subject has no fixed address\n* Subject has previously been genotyped for PGx genes\n* Subject has no current general practitioner\n* Subject is, in the opinion of the Investigator, not suitable to participate in the study\n* Estimated glomerular filtration rate (MDRD) of less than 15 ml\u002Fmin per 1,73m2\n* Patients with advanced liver failure (stage Child-Pugh C)",{"count":151,"type":22},120,[25],"Rationale: In current clinical practice, polypharmacy and patient empowerment are critical yet often overlooked. Polypharmacy, the chronic use of five or more drugs, poses risks such as adverse drug reactions and decreased medication adherence, especially in elderly and multimorbid patients. Despite the interconnected nature of drug-drug and drug-gene pro inter-actions, they are considered separately. Ignoring these interactions can be hazardous, yet clinical trials to investigate them are infeasible due to fast-growing complexity, variability among patients, high costs associated with large-scale studies, and ethical and logistical chal-lenges. Consequently, there is a substantial knowledge gap in managing complex medication regimens in real-life scenarios and providing guidelines to enhance patient empowerment and drug safety. The SafePolyMed project aims to develop a patient-centred framework to define, assess and manage drug-drug, drug-gene and drug-drug-gene interactions. This framework, a web-based medication management centre, will support patients in managing their therapy-related health data, enhancing education and empowerment, and improving patient safety.\n\nObjective: To assess the impact of the developed medication management centre on patient empowerment in polypharmacy patients, thereby improving drug safety. Secondary objec-tives are to explore if the tool is able to identify patients at risk for a drug-drug-gene interaction and lower the adverse drug event rate.\n\nStudy design: The study is a proof of concept study conducted at four institutes located in Germany, Greece, Slovenia and The Netherlands. Polypharmacy patients will use the medi-cation management centre (MMC), which provides curated, patient-specific information about drug interactions and PGx. To assess patient empowerment, patients will receive ques-tionnaires during a 12 week follow-up period.\n\nStudy population: 120 subjects with polypharmacy (defined as the chronic use of 5 or more drugs) of at least 18 years of age, with a first prescription for one of 10 index drugs. The study will be performed at 4 different sites (Leiden (NL), Patras (GR), Ljubljana (SL), Aachen (DE)) to represent different clinical settings across Europe. Each site will recruit 30 patients.\n\nIntervention: The MMC that provides patient centred information on drug-drug interactions and pharmacogenetics affecting personal polytherapy. The MMC will show a selection of high quality publicly available information such as details on different types of medications, includ-ing their uses, side effects and instructions for use, in the language of the patient. This infor-mation is targeted at an individual patient's medication profile to inform patients to better un-derstand and deal with their personal health information, with regard to drug therapy. Patients in the Netherlands, Slovenia and Greece also will receive their PGx profile to further personal-ise the MMC experience.\n\nMain study parameters\u002Fendpoints: The primary outcome is the sense of empowerment and health literacy for participants before and after use of the MMC. Secondary outcomes include an evaluation of the drug-drug-gene interactions and adverse drug events in the study popula-tions compared to matched historical controls.\n\nNature and extent of the burden and risks associated with participation, benefit, and group relatedness: Patients are exposed to the regular treatment. In addition, patients will receive questionnaires at baseline, two, and twelve weeks regarding the use and experience of the medication management centre, and a close-out interview at week twelve. In addition, 10ml of blood will be collected during a venipuncture for pharmacogenetic analyses.\n\nBenefits include having access to the medication management centre for the duration of the study. Additionally, patients will receive their PGx profile. This can be used to individualize drug treatment, based on the Dutch Pharmacogenetics Working Group (DPWG) guidelines.\n\nOverall, minimal risks are expected for subjects as they will receive normal clinical care. In-formation from the MMC will be a curation of existing publicly available data. Any information regarding DDIs and DGIs will be supplemented with a disclaimer that the patient should not adjust their treatment without talking to a healthcare provider.",[29],"2025-12-22",{"date":157,"type":42},"2025-12-30",{"date":159,"type":42},"2025-07-27",{"date":161,"type":22},"2026-08",{"name":163,"class":49},"Leiden University Medical Center",4,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":183,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":50},"100606437","testing-a-smart-medication-dispenser-mobili-to-help-people-with-chronic-conditions-take-their-medicine-100606437","NCT07175545","Testing a Smart Medication Dispenser (Mobili®) to Help People With Chronic Conditions Take Their Medicine","Enhancing Medication Adherence With Mobili®: A Crossover Randomized Controlled Trial in Portuguese Community Pharmacies","MobiMAd@PT RCT","Inclusion Criteria:\n\n* Aged 18 years and above\n* Non-institutionalized diabetes and cardiovascular disease patients\n* At least two medications in the therapeutic regimen\n* Requiring only regular oral medication that can be dispensed in the eDosette\n* Able to handle the use of technological devices (i.e. smartphones)\n\nExclusion Criteria:\n\n* Cognitive impairments preventing independent use of Mobili®\n* Patients using medicines that do not fit or are incompatible with being dispensed in the eDosette (i.e. some capsules, solutions, insulins or GLP-1 analogues, transdermal patches, eye-drops)\n* One participant per household",{"count":174,"type":22},96,[25],"Medication adherence is one of the biggest challenges faced by healthcare systems, especially among people with multiple chronic diseases who take several medications daily. Studies show that up to half of patients do not take their medication as prescribed, which can compromise treatment effectiveness, increase complications, and lead to waste of healthcare resources.\n\nIn this context, several solutions have been developed to help patients organize their therapy, such as dose administration aids (DAAs) used in pharmacies. However, many of these systems are manual, inflexible, or difficult to use.\n\nThis study is part of the MobiMAd@PT project, which will evaluate Mobili®, a portable digital medication dispenser developed in Norway. Mobili® allows patients to automatically receive the right medication at the right time and comes with a real-time monitoring system, enabling healthcare professionals to detect missed doses and provide timely support.\n\nThe main goal of this study is to assess the effectiveness of Mobili® in improving medication adherence among patients with polypharmacy in Portugal and to understand whether this type of technology can be useful and applicable in the context of Portuguese community pharmacies. Your participation will contribute to the development of new ways to manage health at home, with the support of pharmacists and technology.",[178,179,29,180,181,182],"Dose Administration Aids","Medication Adherence","Technology in Health","Diabetes","Cardiovascular Diseases",[184,179,185,186],"Digital Health","Automatic Medicine Dispenser","Community Pharmacy","2025-09-08",{"date":189,"type":42},"2025-09-16",{"date":191,"type":22},"2025-10-15",{"date":193,"type":22},"2026-06-30",{"name":195,"class":49},"Lusofona University",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":218,"locationsCount":50},"100594710","improving-medication-management-in-world-trade-center-responders-100594710","NCT07022990","Improving Medication Management in World Trade Center Responders","Promoting Healthy Aging Among WTC Responders: Frailty Trajectories And Intervention Strategies","Inclusion Criteria:\n\n* A WTC responder already enrolled in the \"Promoting Healthy Aging Among WTC Responders: Frailty Trajectories and Intervention Strategies\" study cohort\n* aged 50 years or older, and\n* taking one of the five medication classes:\n\n  * proton pump inhibitors (PPIs),\n  * benzodiazepine (BZs) and\n  * non-benzodiazepine sedative hypnotics (\"Z-drugs\"),\n  * first-generation antihistamines (FGA), and\n  * skeletal muscle relaxants (SMR).\n\nExclusion Criteria:\n\n* None","50 Years",{"count":205,"type":22},50,[25],"By 2030, the majority of World Trade Center (WTC) rescue and recovery workers (responders) will be aged 65 and over and at risk for aging-related conditions and consequences including the concurrent use of five or more medications (i.e., polypharmacy). The purpose of this research study is to investigate an educational approach targeting polypharmacy through de-prescribing unnecessary and burdensome medications via the support of informed discussions between WTC responders and their prescribing physicians.",[29],[210,211],"Deprescribe","Medication management","2025-06-08",{"date":214,"type":42},"2025-06-15",{"date":216,"type":42},"2025-04-08",{"date":193,"type":22},{"name":219,"class":49},"Icahn School of Medicine at Mount Sinai",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":118,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":242,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":261,"locationsCount":4},"100583907","holistic-integration-for-healthy-longevity-and-aging-in-place-100583907","NCT06882434","Holistic Integration for Healthy Longevity and Aging in Place","Holistic Integration for Healthy Longevity and Aging in Place - Establishing Full-spectrum Community-based Care System for Older People to Maintain Wellbeing Pursuing Abilities","HIHOPE","Inclusion Criteria:\n\n* Age ≥55 years (includes older adults and pre-elderly individuals).\n* No severe functional disability (must be able to walk independently, use assistive devices, or operate a wheelchair independently).\n* No severe cognitive impairment (must be able to respond appropriately to verbal questions).\n\nExclusion Criteria:\n\n* Irregular community participation (less than once per week in the target community).\n* Mild dementia or greater (assessed during screening). If identified, family members will be notified, and they retain the right to withdraw the participant unconditionally.",{"count":229,"type":22},600,[25],"Background:\n\nTaiwan is experiencing rapid population aging, with a growing prevalence of chronic diseases and functional impairments among older adults. Existing Integrated Care for Older People (ICOPE) programs focus primarily on screening but lack sufficient follow-up and intervention. In response, the HI-HOPE Project was developed to establish a community-based, multidisciplinary intervention model to enhance intrinsic capacity and promote healthy aging in rural elderly populations.\n\nSurvey and Screening:\n\nThe study will be conducted in 30 community centers across Yunlin County, targeting older adults aged ≥55 years. Participants will undergo biannual screenings over two years, assessing cognitive function, depression, mobility, vitality (nutrition), hearing, vision, osteoporosis, polypharmacy, urological health, and social participation \\& welfare.\n\nIntervention:\n\nParticipants will be randomly assigned to either:\n\nHI-HOPE Integrated Care Group:\n\nOn-Site Community Interventions: Exercise training, mindfulness, social activities, oral and swallowing rehabilitation, hearing and vision training.\n\nTelehealth \\& Remote Education: Digital health monitoring, remote consultations, and health education.\n\nReferral Services: Access to specialized medical care, transportation assistance, and follow-up support.\n\nControl Group: Standard community care services without additional structured interventions.\n\nOutcome Measures:\n\nPrimary outcomes include changes in intrinsic capacity of functional health metrics, including abnormalities of I-COPE components (mobility, cognitive status, depression, hearing, vision, vitality) . Secondary outcomes assess quality of life, activities of daily living, hospitalization, emergency visits, falls, and mortality rates over two years.\n\nSignificance:\n\nThis project integrates digital health technologies, interdisciplinary care, and community-based interventions to improve elderly health outcomes. The findings will guide the future scalability of integrated aging care models in Taiwan and beyond.",[233,234,235,236,237,238,239,240,241,29],"Cognitive Decline","Sarcopenia","Depression Disorders","Nutrition Disorder","Swallowing Difficulties","Hearing Disorder","Visual Disorder","Osteoporosis","Urologic Disorders",[226,243,244,245,246,247,248,249,250,251,252,253,254],"I-COPE","dementia","depression","dysphagia","nutrition","sarcopenia","frailty","hearing disorder","visual disorder","osteoporosis","urologic disorder","polypharmacy","2025-03-20",{"date":257,"type":42},"2025-03-25",{"date":259,"type":22},"2025-03-15",{"date":139,"type":22},{"name":262,"class":49},"National Taiwan University Hospital",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":271,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":50},"100479744","reduction-of-polypharmacy-in-elderly-people-with-multiple-diseases-100479744","NCT05526963","Reduction of Polypharmacy in Elderly People With Multiple Diseases","Reduction of Polypharmacy in Elderly People With Multiple Diseases - a Stepped Wedge Cluster-randomized Controlled Trial","RED","Inclusion Criteria:\n\n* ≥ 5 longterm medications (\\> 6 months) (polypharmacy)\n* ≥ 3 chronic diseases (multimorbidity)\n* ≥ 1 family doctor consultation within the last 6 months\n\nExclusion Criteria:\n\n* Patients with a critically reduced life expectancy\n* Patients who cannot autonomously visit the family practice\n* Patients who cannot participate in the informed consent process\n* Patients who are residing in a nursing home\n* Patients with dementia or a mental of behavioral disorder ICD-10 F00-F99\n* Patients who are participating in another medical study with a focus on polypharmacy or multimorbidity","70 Years",{"count":273,"type":22},1146,[25],"Elderly GP patients are often treated with five or more medications and therefore prone to adverse drug reactions (ADR). Potentially inappropriate prescriptions (PIPs) lead to increased adverse events like falls, hospitalizations and mortality. The primary aim of this study to reduce the frequency of ADRs in multimorbid patients aged 70 years and older by reducing polypharmacy.",[29,277],"Multimorbidity",[279,29,277,280],"Primary Care","Drug-Related Side Effects and Adverse Reactions","2025-01-07",{"date":283,"type":42},"2025-01-09",{"date":285,"type":42},"2024-05-30",{"date":287,"type":22},"2025-12-31",{"name":289,"class":49},"Martin-Luther-Universität Halle-Wittenberg",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":297,"targetDuration":299,"studyType":121,"phases":4,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":4},"100571715","the-critical-care-recovery-program-use-of-a-structured-clinic-visit-to-reduce-adverse-drug-events-in-icu-survivors-100571715","NCT06723860","The Critical Care Recovery Program: Use of a Structured Clinic Visit to Reduce Adverse Drug Events in ICU Survivors","CCRP","Inclusion Criteria:\n\n* Patient being discharged to ward, home or repatriated to local health centre AND ONE OR MORE OF\n\n  * Duration of mechanical ventilation \\>72 hours\n  * Length of stay in critical care \\>96 hours\n  * Out of hospital arrest\n  * Maternal critical illness\n  * Trauma\n  * Significant ICU delirium\n  * Unexpected adverse outcomes of planned treatment\n\nExclusion Criteria:\n\n* Patient discharged for palliative care or expected to die within the next two months",{"count":298,"type":22},3000,"1 Year","Background and Objective: Intensive Care Units (ICUs) save lives, but many ICU survivors face ongoing health issues, including adverse drug events (ADEs) from medications started during their hospital stay. These ADEs lead to emergency department visits and hospital admissions. Our project aims to improve the health of ICU survivors by creating a clinic that focuses on managing post-ICU health. The clinic will track and address medical issues that arise after ICU discharge and focus on deprescribing, or safely stopping, medications that may no longer be needed or could be harmful.\n\nProject Plan: The clinic will be set up within the CARES clinic at VGH. Patients will be enrolled when they leave the ICU and will have follow up visits after hospital discharge. During these visits, the team will review each patient's medications and develop a personalized plan to reduce or stop unnecessary medications. We will also monitor patients for any new health issues that arise and provide eduction to patients and caregivers about managing their health.\n\nResearch and Evaluation: We will collect and analyze data on patient health outcomes, including the incidence of ADEs, hospital reeadmissions, and emergency department visits. We hope to show that patients who receive follow up care have better health outcomes and use fewer healthcare resources than a historical cohort. This data will help us demonstrate the cost-effectiveness of the clinic and support the need for expanding ICU follow up programs in British Columbia.\n\nLong-term goals: We plan to establish a post-ICU care working group and expand the clinic model to other hospitals. Over the long term, we hope to standardize post-ICU care across BC, ensuring that all ICU survivors have access to comprehensive follow up care. This project will also lay the groundwork for future research on deprescribing medications for ICU related complications, which tend to improve or resolve once critical illness has resolved. The CCRP clinic will provide a setting to conduct clinical deprescription trials to establish whether long-term treatment of these complications is necessary.\n\nConclusion: Establishing a post-ICU discharge follow up clinic with a focus on deprescription has the potential to improve the long-term health and quality of life for ICU survivors. By reducing unnecessary medications, we can prevent complications, reduce hospital readmissions and demonstrate the value of comprehensive post-ICU follow up care.",[302,29,303,304],"Post Intensive Care Syndrome (PICS)","Adverse Drug Events","Critical Care, Intensive Care","2024-12-04",{"date":307,"type":42},"2024-12-09",{"date":309,"type":22},"2025-01-30",{"date":311,"type":22},"2027-12-30",{"name":313,"class":49},"University of British Columbia",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":322,"targetDuration":324,"studyType":121,"phases":4,"briefSummary":325,"conditions":326,"keywords":345,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":50},"100409713","acutelines-a-large-data-biobank-of-acute-and-emergency-medicine-100409713","NCT04615065","Acutelines: a Large Data-\u002FBiobank of Acute and Emergency Medicine","Acutelines: a Large Biobank Aiming to Improve Early Recognition of Acute Diseases, Contribute to the Development of Personalized Medicine and Optimize Short- and Long-term Outcome","Acutelines","Inclusion Criteria, at least one of the following:\n\n* Triaged as one of highest two triage categories (red or orange) according to the Manchester triage system;\n* Triaged as the third highest triage category (yellow) and arrival by EMS of Helicopter Emergency Medical Service (HEMS;\n* Shock\n* Suspicion of sepsis (based on either physicians' suspicion, Sepsis-2 or Sepsis-3 criteria)\n* Acute kidney injury (AKI)\n* Anaphylactic reaction\n* Syncope\n* Intoxication\n* Thrombosis\n* Pulmonary embolism\n* Bleeding while using anti-coagulant drugs\n* Gastro-intestinal bleeding\n* Electrolyte disturbance\n\nExclusion Criteria:\n\n* Referred for organ transplantation as recipient\n* Transfer from other hospital\n* Accidental contact patient material (i.e. internal work-related accident)\n\nWhile data- and imaging will be collected from all these patients, biomaterials will only be collected from patients fulfilling the first criterion (i.e. triaged as one of highest two triage categories \\[red or orange\\] according to the Manchester triage system) and from patients with shock or a suspicion of sepsis.",{"count":323,"type":22},35000,"5 Years","Research in acute care faces many challenges, including enrollment challenges, legal limitations in data sharing, limited funding, and lack of singular ownership of the domain of acute care. To overcome some of these challenges, the Center of Acute Care of the University Medical Center Groningen in the Netherlands, has established a de novo data-, image- and biobank named \"Acutelines\". Acutelines is initiated to improve recognition and treatment of acute diseases and obtain insight in the consequences of acute diseases, including factors predicting its outcome. Thereby, Acutelines contributes to development of personalized treatment and improves prediction of patient outcomes after an acute admission.",[327,328,329,330,331,332,333,334,335,336,337,29,338,339,340,341,342,343,344],"Acute Disease","Sepsis","Pneumonia","Frailty","Complication of Treatment","Pulmonary Embolism","Thrombosis","Acute Kidney Injury","Electrolyte Disturbance","Hemorrhage","Shock","Intoxication by Drug","Emergencies","Urinary Tract Infections","Skin Infection","Syncope","Anaphylaxis","Dyspnea",[346,328,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367],"Acute disease","Emergency Medical Service (EMS)","Outcome","Precision medicine","Personalized medicine","Emergency medicine","Multidisciplinary","General practitionar","Pharmacy","Hospitalization","Health insurance","Mortality","Quality of life (QoL)","Overcrowding","Patient logistics","Point-of-care ultrasound (POCUS)","Helicopter Emergency Medical Service (HEMS)","Biobank","Databank","Electrophysiological waveforms","Electrocardiogram (ECG)","Plethysmogram","2024-06-12",{"date":370,"type":42},"2024-06-13",{"date":372,"type":42},"2020-09-01",{"date":374,"type":22},"2030-09-01",{"name":376,"class":49},"University Medical Center Groningen",{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":23,"phases":386,"briefSummary":387,"conditions":388,"keywords":393,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":405},"100537125","evaluation-of-medication-management-service-100537125","NCT06273761","Evaluation of Medication Management Service","Primary Care Community Pharmacy Project: Evaluation of Medication Management Service","Inclusion Criteria:\n\n* aged 18 years or above\n* diagnosed with Type 2 diabetes mellitus and\u002For hypertension\n* having regular follow-up on Type 2 diabetes mellitus and\u002For hypertension at Hospital Authority\n* no A\\&E admission\u002Fhospitalization in the past 3 months\n* no recent changes in medication regimen in the past 3 months\n* polypharmacy (taking 5 or more chronic medications)\n* using at least 1 high-risk medication (Anticoagulants, Oral hypoglycaemics, Insulins, psychotropic medications or immunosuppressants)\n* able to communicate in Cantonese and\u002For English\n\nExclusion Criteria:\n\n* aged below 18\n* unable to give informed consent\n* unable to communicate in Cantonese and\u002For English",{"count":385,"type":22},640,[25],"Medication management services (MMS) is a pharmacist-led service of optimizing the medication use and health outcomes, by promoting medication safety and enhancing the ability in self-management of health and diseases of patients and their caregivers. Yet, only limited evidence on the implementation of MMS service in Hong Kong is available. The goal of this clinical trial is to evaluate the cost effectiveness and effects of implementing MMS in community pharmacies owned by 8 non-government organizations (NGOs) in Hong Kong on humanistic and clinical outcomes in patients with hypertension and\u002For type II diabetes mellitus. The clinical trial aims to look into the following aspects:\n\n* To evaluate the perception and satisfaction of patients on MMS service\n* To investigate whether MMS could improve patients' adherence to their medication regimen, health-related quality of life, health outcomes and health service utilization, as well as their ability to understand and cope with their illness and drug-related problems\n* To identify and categorize the types of drug-related problems identified during MMS\n* To evaluate the cost-effectiveness of implementing MMS in community pharmacies\n\nMMS services will be rolled out in a total of 8 NGO community pharmacies progressively (2 pharmacies per phase) in 4 successive phases. Participants will complete the questionnaires at the following time points throughout the trial, namely 1) during recruitment, 2) baseline (1 month before MMS), 3) 3 months after MMS begins, 4) 12 months after MMS begins, and 5) 24 months after MMS begins. Researchers will compare the results of questionnaires conducted at different time points to identify the potential changes in the effects of MMS. Furthermore, researchers will link up the electronic health records of the participants and identify the potential changes in the health outcomes and health service utilizations after receiving MMS.",[179,389,390,391,29,392],"Medication Safety","Diabetes Mellitus, Type 2","Hypertension","High Risk Medications",[394,395],"Medication Management Service","Community pharmacy service","2024-02-21",{"date":398,"type":42},"2024-02-23",{"date":400,"type":42},"2024-02-06",{"date":402,"type":22},"2027-05-01",{"name":404,"class":49},"The University of Hong Kong",8,{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":17,"minAge":271,"maxAge":4,"enrollmentInfo":413,"targetDuration":414,"studyType":121,"phases":4,"briefSummary":415,"conditions":416,"keywords":419,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":4},"100458299","individual-risk-profiles-for-adverse-drug-reactions-in-geriatric-patients-100458299","NCT05247814","Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients","Individual Patient Risk Profiles for Adverse Drug Reactions: Establishing a Consecutive Research Cohort in an Interdisciplinary Polypharmacy Consultation Service of a Geriatric University Outpatient Department","Inclusion Criteria:\n\n* 70 years or older\n* Current drug therapy with three or more drugs\n* Being a patient in the interdisciplinary polypharmacy consultation service of the geriatric university outpatient clinic\n* Sufficient mobility (minimum: Wheelchair mobility)\n* Written informed consent of the patient or the legal representative\n\nExclusion Criteria:\n\n* No sufficient communication possible\n* Patients classified as terminally ill by the medical staff\n* Patients, that are incapable to give their informed consent and who do not have a legal representative",{"count":120,"type":22},"6 Months","This project will generate a prospective cohort of geriatric patients with polypharmacy which will be characterized for vulnerability profiles of adverse drug reactions.",[29,417,418,280],"Pharmacogenetics","Pharmacogenomic Testing",[420,179,421,422,423,424,425,426,427,428,429,430],"Geriatric Assessment","Aged","Aged, 80 and over","Medication therapy management","Pharmacists","Geriatricians","Clinical Pharmacology","Medication reconciliation","Hospital pharmacy services","Hospital outpatient clinics","nterdisciplinary Health Team","2022-06-17",{"date":433,"type":42},"2022-06-23",{"date":435,"type":22},"2022-07",{"date":437,"type":22},"2032-02",{"name":439,"class":49},"RWTH Aachen University"]